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Background: Tuberculosis (TB) is one of the most serious health problems in Myanmar. 
Because TB drug resistance is associated with genetic mutation(s) relevant to responses 
to each drug, genotypic methods for detecting these mutations have been proposed to 
overcome the limitations of classic phenotypic drug susceptibility testing (DST). We ex-
plored the current estimates of drug-resistant TB and evaluated the usefulness of geno-
typic DST in Myanmar.
Methods: We determined the drug susceptibility of Mycobacterium tuberculosis isolated 
from sputum smear-positive patients with newly diagnosed pulmonary TB at two main TB 
centers in Myanmar during 2013 by using conventional phenotypic DST and the Geno-
Type MTBDRplus assay (Hain Lifescience, Germany). Discrepant results were confirmed 
by sequencing the genes relevant to each type of resistance (rpoB for rifampicin; katG 
and inhA for isoniazid).
Results: Of 191 isolates, phenotypic DST showed that 27.7% (n=53) were resistant to at 
least one first-line drug and 20.9% (n=40) were resistant to two or more, including 18.3% 
(n=35) multidrug-resistant TB (MDR-TB) strains. Monoresistant strains accounted for 
6.8% (n=13) of the samples. Genotypic assay of 189 isolates showed 17.5% (n=33) 
MDR-TB and 5.3% (n=10) isoniazid-monoresistant strains. Genotypic susceptibility re-
sults were 99.5% (n=188) concordant and agreed almost perfectly with phenotypic DST 
(kappa=0.99; 95% confidence interval 0.96-1.01). 
Conclusions: The results highlight the burden of TB drug resistance and prove the useful-
ness of the genotypic DST in Myanmar.
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INTRODUCTION
Tuberculosis (TB) is a major global health problem and the fore-
most cause of death from a single infectious agent, Mycobacte-
rium tuberculosis. Nearly nine million new cases of TB and 1.4 
million deaths occurred worldwide in 2011. With the emergence 
of multidrug-resistant (MDR) and extensively drug-resistant 
(XDR) strains, TB has become an even greater threat [1]. Myan-
mar is one of the 22 countries with high-burden TB and among 
27 countries with high-burden MDR-TB. An estimated 180,000 
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new TB cases occurred in Myanmar in 2011, and the propor-
tion of MDR-TB was 4.2% among these cases and 10.0% 
among previously treated cases according to the second nation-
wide drug-resistant TB survey (2007-2008) [1].
 The identification of resistant strains through drug susceptibil-
ity testing (DST) and subsequent appropriate treatment might 
be the most effective strategy for controlling the spread of drug-
resistant TB. The phenotypic DST widely used in developing 
countries is a proportion method that uses fixed concentrations 
of first-line TB drugs: isoniazid (INH), rifampicin (RIF), etham-
butol (EMB), and streptomycin (SM). This method is simple and 
cost-effective; however, the results require a long time to obtain 
and can be unreliable in some diagnostic examination settings. 
 Because TB drug resistance is associated with mutation(s) in 
the genes relevant to responses to each drug, genotypic meth-
ods for detecting mutations in these genes have been proposed 
to overcome the limitations of phenotypic DST [2]. A promising 
genotypic DST, the line-probe assay (LiPA), was endorsed by 
WHO in its 2008 policy statement for use with smear-positive 
pulmonary specimens [3]. Commercially available LiPAs for the 
rapid detection of INH and RIF resistance are based on se-
lected numbers of commonly reported mutations. One LiPA, 
GenoType MTBDRplus (Hain Lifescience, Nehren, Germany), 
was designed for simultaneous detection of the most important 
rpoB mutations, which confer RIF resistance, and katG and 
inhA mutations, which confer high-level INH resistance [4].
 We used both phenotype-based conventional DST and a 
commercially available genotypic DST (GenoType MTBDRplus) 
to investigate TB drug resistance in patients with newly diag-
nosed pulmonary TB in Myanmar to obtain more accurate infor-
mation on drug resistance, evaluate the usefulness of GenoType 
MTBDRplus, and characterize genetic alterations specific to TB 
in Myanmar.
METHODS
1. Patient enrollment and sample collection
A cross-sectional descriptive study was carried out at the Latha 
TB Diagnostic Centre (Yangon) and Mandalay Regional TB Cen-
tre (Mandalay) in Myanmar from January to August 2013. The 
WHO case definition was applied, in which a new TB case was 
defined as a sputum- smear positive patient who had never re-
ceived treatment for TB or who had taken TB drugs for less 
than one month [1]. Two sputum samples were collected from 
each patient after obtaining written informed consent. The fol-
lowing definition was applied to determine smear-positive TB: 
one or more initial sputum smear examinations (direct smear 
microscopy) positive for acid-fast bacilli (AFB) or one AFB-posi-
tive sputum examination plus radiographic abnormalities con-
sistent with active pulmonary TB as determined by a clinician 
[1]. Demographic characteristics were recorded in the pro 
forma when patients were enrolled.
2. Study patients
During the study period, 212 sputum samples from newly diag-
nosed pulmonary TB patients were subjected to culture. The 
mean age of the patients was 39±16.4 yr, and 128 (60.4%) 
were males. After excluding 21 contaminated or unculturable 
samples, 191 M. tuberculosis isolates comprising 142 (74.3%) 
from the Yangon region and 49 (25.7%) from the Mandalay re-
gion were subjected to phenotypic and genotypic DST.
3. Isolation of M. tuberculosis and phenotypic DST 
Isolation of M. tuberculosis from sputum samples and DST with 
conventional culture was performed at the National TB Refer-
ence Laboratory (NTRL; Yangon, Myanmar) and Upper Myan-
mar TB Laboratory (Mandalay, Myanmar). M. tuberculosis was 
isolated from sputum samples according to the WHO method 
[5]. Sputum samples were decontaminated with N-acetyl-L-cys-
teine sodium hydroxide. After centrifugation at a speed of 3,000-
3,500g for 15 min, the pellet was suspended in 1 mL 1×phos-
phate-buffered saline, inoculated on two Lowenstein-Jensen (L-
J) media slants, and incubated at 37°C for 6-8 weeks depending 
on the time required for the organisms to become evident. My-
cobacterial growth was monitored every week. The M. tuberculo-
sis isolates were identified according to growth rate and colony 
morphology. The Capilia TB test (Tauns, Numazu, Japan), an 
immunochromatographic assay that uses a monoclonal antibody 
to detect MPB64 antigen, was used to differentiate M. tubercu-
losis complex from non-tuberculous mycobacteria. 
 Phenotypic DST was carried out on confirmed M. tuberculo-
sis isolates. The test was performed on L-J media containing 
INH (0.2 μg/mL), RIF (40 μg/mL), SM (4 μg/mL), and EMB (2 
μg/mL) according to the WHO-recommended proportional 
method for all primary isolates [6]. Inocula were cultured in a 
37°C incubator for 6 weeks, and the results were interpreted as 
susceptible or resistant. The standard criterion of the proportion 
method for classifying a strain as resistant was the ratio of the 
number of colonies obtained on drug-containing medium to the 
number of colonies obtained on drug-free medium (growth of ≥  
1% of colonies). Any-drug resistance was defined as resistance 
to one or more first-line drugs. Monoresistance was defined as 
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resistance to only one of the four drugs. 
4. Genotypic detection of INH and RIF resistance
Genotypic detection of INH and RIF resistance was carried out 
at Pusan National University Yangsan Hospital (Yangsan, Ko-
rea). The GenoType MTBDRplus, a reverse hybridization line 
probe assay, was performed according to the manufacturer’s 
recommendations. Multiplex PCR was used to amplify the 
genes responsible for drug resistance, including katG, inhA, and 
rpoB, and the resulting biotin-labeled amplicons were hybrid-
ized to DNA probes that affixed to the membrane. DNA probes 
for each gene consisted of wild-type (WT) and mutant (MUT) 
samples. Resistance to INH and RIF was defined as either (1) 
missing WT probe signal with MUT probe signal, or (2) missing 
WT probe signal.
5.  Confirmation of discrepant results between phenotypic 
and genotypic DSTs 
The genotypic and phenotypic DST results were compared. 
Further examinations were performed with additional pheno-
typic DST or DNA sequencing (rpoB for RIF and katG and inhA 
for INH) when the results disagreed. Each discordant gene re-
gion was amplified with PCR, and direct sequencing of PCR 
products was carried out by Genotech (Daejeon, Korea). The 
sequencing results were analyzed with the CLC Main Work-
bench (CLC bio, Aarhus, Denmark) at the International Tuber-
culosis Research Center (Changwon, Korea).
6. Statistical analysis 
The results were analyzed with the SPSS statistical software 
package, version 16 (SPSS Inc., Chicago, IL, USA). Drug-sus-
ceptible and drug-resistant cases were documented as the per-
centages of the total study population, and the drug-resistance 
pattern in newly diagnosed patients was determined. The resis-
tance results of phenotypic and genotypic DST were tested for 
kappa agreement [7].
7. Ethics approval 
This study was approved by the Ethics Review Committee, De-
partment of Medical Research, Yangon, Myanmar.
RESULTS
1.  Drug-resistance patterns of M. tuberculosis isolates from 
newly diagnosed patients
Of the 191 M. tuberculosis isolates, 27.7% (n=53) were resis-
tant to at least one first-line drug, and 40 (20.9%) were resistant 
to two or more, including 35 (18.3%) classified as MDR-TB 
strains. Monoresistant strains accounted for 6.8% (n=13), in-
cluding 2.1% (n =4) INH-monoresistant strains and 4.7% 
(n=9) SM-monoresistant strains. The total resistance rates were 
as follows: INH (44; 23.0%), RIF (35; 18.3%), EMB (15; 7.9%), 
and SM (41; 21.5%).
2. Gene mutation patterns in drug-resistant strains 
Among the 191 tested strains, two had a PCR inhibitor and 
were excluded from genotypic analysis. Genotypic assay of the 
remaining 189 samples showed 17.5% (n =33) MDR-TB 
strains and 5.3% (n=10) INH-monoresistant strains. Among 
the 33 RIF-resistant isolates, the S531L mutation, which is the 
most prevalent, was present in 63.6% (n=21). Of the 43 INH-
resistant strains, 93.0% (n=40) had a mutation at the S315T1 
(AGC→ACC) codon of katG (Table 1).
3.  Comparison of phenotypic and genotypic TB drug 
susceptibility patterns 
After isolates with discordant phenotypic and genotypic DST re-
sults were confirmed with additional phenotypic DST or the se-
Table 1. Distribution of mutation patterns in rpoB, katG, and inhA among drug-resistant Mycobacterium tuberculosis isolates
Drug resistance N and proportion of resistant gene Mutation type
N (%) in MDR strains 
(n=33)
N (%) in INH monoresistant strains 
(n=10) 
RIF (n=33) rpoB (33, 100%) L511P 1 (3.0) -
D516V 2 (6.1) -
H526Y 9 (27.3) -
S531L 21 (63.6) -
INH (n=43†) katG (40, 93.0%) S315T1* 31 (72.1) 9 (20.9)
inhA (3, 7.0%) C15T 2 (4.7) 1 (2.3)
*S315T1 means AGC→ACC/Ser→Thr exchange; †includes 33 INH-resistant isolates that were also resistant to RIF, composing 33 MDR isolates.
Abbreviations: INH, isoniazid; MDR, multidrug resistant; RIF, rifampicin.
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quencing of discordant genes, genotypic DST  results were 
99.5% (188/189) concordant with the phenotypic DST results. 
One isolate, which was resistant to INH on phenotypic DST and 
susceptible to INH in the GenoType MTBDRplus assay, was 
confirmed as resistant without any mutation in the target genes 
(katG or inhA). The genotypic DST had almost perfect agree-
ment with the phenotypic DST (kappa=0.99; 95% confidence 
interval [CI] 0.96-1.01); Table 2). The 17 discordant phenotype 
and genotype results are listed in Table 3.
DISCUSSION 
Drug resistance is a key cause of treatment failure in TB, partic-
ularly when strains are resistant to the primary drugs, INH and 
RIF, which results in the development of MDR-TB. Managing 
the increasing number of MDR-TB cases is a crucial part of the 
STOP TB strategy and a component of all TB control programs 
[8]. MDR-TB strains can be transmitted in the community, re-
placing susceptible strains and consequently making first-line 
regimens inadequate for achieving high cure rates. Drug resis-
Table 2. Comparison of phenotypic and genotypic drug susceptibility tests
Drug susceptibility test Type of drug resistance N of isolates
Phenotypic DST
Susceptible Resistant
Genotypic DST INH Susceptible 145     1* Kappa=0.99 (95% CI 0.96-1.01)
Resistant 0 43
RIF Susceptible 156   0
Resistant 0 33
*isolate no. 1998 in Table 3. 
Abbreviations: DST, drug susceptibility testing; INH, isoniazid; RIF, rifampicin; CI, confidence interval.
Table 3. Confirmation of 17 discordant Mycobacterium tuberculosis isolates via additional phenotypic drug susceptibility test and DNA se-
quencing
Isolate No.
First phenotypic DST
Genotypic DST (GenoType 
MTBDRplus assay)
Second phenotypic DST DNA sequencing Final 
interpretation of 
results RIF INH RIF INH RIF INH RIF (rpoB) INH (katG/inhA)
381 R R S S - - NM NM Concordant*
606 S S S R S R - - Concordant*
674 R R S S - - NM NM Concordant*
677 R R S S - - NM NM Concordant*
779 R R S S - - NM NM Concordant*
1417 R R S R - - NM katG: 315AGC to ACC Concordant*
1419 R S S S S S NM NM Concordant*
1542 S S S R S R NM inhA: -15 C to T Concordant*
1864 S S R R R R 531TCG to TTG katG:315AGC to ACC Concordant*
1865 S S R R S R 531TCG to TTG katG:315AGC to ACC Concordant†
1868 S R S S NM NM Concordant*
1998 S R S S S R NM NM Discordant‡
2215 S S R S R R 531TCG to TTG inhA: -15 C to T Concordant§
U3 S S R R R R - - Concordant*
U5 S S R R R R 531TCG to TTG KatG-315AGC to ACC Concordant*
U9 S R S S S S - - Concordant*
U10 S S S R S R - - Concordant*
*first DST error; †both first and second DST error; ‡mutation other than those in target genes might be involved; §GenoType MTBDRplus assay test error.
Abbreviations: DST, drug susceptibility testing; INH, isoniazid; NM, no mutation; R, resistant; RIF, rifampicin; S, susceptible.
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tance in new cases has been used to evaluate recent transmis-
sion and can be used as a proxy for acquired resistance in a 
previously treated group.
 In Myanmar, the second nationwide drug resistance survey 
(2007-2008) showed an MDR-TB rate of 4.2% among new pa-
tients and 10.0% among previously treated patients [1]. Previ-
ous studies carried out at the Yangon Divisional TB Center, a 
major referral center in Myanmar, during 1994-2004 found that 
the MDR-TB and any-drug resistance rates were 1.25-4.2% 
and 15.8-35.3%, respectively [9-12].
 The present study showed a high rate of MDR-TB (18.3%) 
and any-drug resistance rate of 27.7% among new TB cases as 
determined with a phenotypic method. These rates were much 
higher than those reported in previous nationwide and TB cen-
ter-based studies. According to the 2012 Annual Report of the 
Myanmar National TB Program, Yangon had the highest TB 
case detection rate (112%), and many TB patients living in Yan-
gon had one of the statistically significant risk factors for MDR-
TB (odds ratio [OR]=3.0; 95% CI=1.5  5.8; P =0.014). In the 
present study, 74.3% of tested MTB isolates were from Yangon, 
which may account for the high drug-resistance rate [13]. INH 
resistance was most common. The individual anti-drug resis-
tance pattern was similar to that reported in previous studies 
abroad and in Myanmar [9-12, 14].
 The MDR-TB rate in Myanmar is among the highest in South-
east Asia [1], and the present study showed a high MDR-TB 
rate among new smear-positive pulmonary TB patients. The 
drug resistance results of newly diagnosed patients may reflect 
the primary resistance to first-line TB drugs in Myanmar, al-
though primary resistance is difficult to determine because pa-
tients may not know or may deny that they have had previous 
TB treatment. The high prevalence of drug resistance in Myan-
mar highlights the need for a control program to improve case 
management and strengthen TB control strategies.
 Drug resistance in M. tuberculosis develops as a result of 
random mutations in the genes responsible for resistance to 
each drug [15, 16]. In the case of RIF, 95-98% of resistance 
develops because of mutations in the 81-bp core region (RIF 
resistance-determining region or hot spot) of the β subunit of 
the RNA polymerase gene (rpoB), which results in peptide al-
terations at codon 531 or codon 526. The most common muta-
tions are S531L and H526Y [14, 15]. The molecular basis of 
INH resistance is more complex and is associated with genes 
such as katG, inhA, ahpC, and oxyR [17]. Approximately 50-
95% of INH-resistant strains contain mutations in codon 315 of 
katG, whereas 20-35% contain mutations in the inhA regulatory 
region [4].
 In the present study, among the 33 RIF-resistant isolates 
found with genotypic DST, the S531L mutation was the most 
common at 63.6% (n=21). The H526Y mutation was the sec-
ond most common, accounting for 27.3% (n=9) of MDR strains. 
 Of the 43 INH-resistant strains, 93.02% (n=40; 31 MDR 
strains and nine INH-monoresistant strains) had a mutation in 
the S315T1 region of katG, and only 6.97% (n=3; two MDR 
strains and one monoresistant strain) had a mutation in the 
C15T region of inhA. This finding was consistent with the previ-
ous results  [15, 16]. The high prevalence of katG mutations 
accounts for a high proportion of INH resistance in countries 
with high TB prevalence, presumably as a result of the trans-
mission of these strains in a high-burden setting [18]. No other 
mutation in ahpC or oxyR was observed in this study, which 
suggests that those mutations are infrequently involved in INH 
resistance in Myanmar.
 The overall concordance between phenotypic and genotypic 
DST was 99.5% (188/189) after the confirmation of these sam-
ples with additional phenotypic DST and DNA sequencing. Sim-
ilar results were reported in previous studies, with values rang-
ing from 88.9% to 100% [19-22]. When we analyzed the phe-
notypic and genotypic results with kappa statistics, the geno-
typic assay showed almost perfect agreement with phenotypic 
DST (kappa=0.99; 95% CI 0.96-1.01). The one discordant iso-
late was susceptible to INH in the GenoType MTBDRplus assay 
but resistant to INH without any mutation in the target genes. 
Mutation other than that in the target gene might be involved in 
the resistance in this isolate. The high MDR-TB rate, high accu-
racy of genotypic DST, and common drug resistance-mutation 
pattern found in the present study suggested that genotypic 
DST should be more widely used as a routine test to determine 
drug susceptibility in newly diagnosed TB patients. Genotypic 
DST may also lead to the rapid detection of MDR-TB cases and 
be invaluable in preventing the transmission of drug-resistant 
strains in Myanmar. In conclusion, this study highlighted the 
high prevalence of drug resistance among new pulmonary TB 
cases in Myanmar and the usefulness of genotypic DST for de-
termining drug susceptibility in TB patients and for the rapid 
and accurate diagnosis of TB in Myanmar.
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